A phase I single-blind clinical trial to evaluate the safety of oil palm phenolics (OPP) supplementation in healthy volunteers

Abstract Plant phenolics are being increasingly consumed globally with limited scientific and clinical evidence pertaining to safety and efficacy. The oil palm fruit contains a cocktail of phenolics, and palm oil production results in high volumes of aqueous by-products enriched in phenolics and bio...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Syed Fairus, Soon-Sen Leow, Isa Naina Mohamed, Yew-Ai Tan, Kalyana Sundram, Ravigadevi Sambanthamurthi
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/629fde5c12244eb9a11929d484d9d76e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:629fde5c12244eb9a11929d484d9d76e
record_format	dspace
spelling	oai:doaj.org-article:629fde5c12244eb9a11929d484d9d76e2021-12-02T15:07:51ZA phase I single-blind clinical trial to evaluate the safety of oil palm phenolics (OPP) supplementation in healthy volunteers10.1038/s41598-018-26384-72045-2322https://doaj.org/article/629fde5c12244eb9a11929d484d9d76e2018-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-26384-7https://doaj.org/toc/2045-2322Abstract Plant phenolics are being increasingly consumed globally with limited scientific and clinical evidence pertaining to safety and efficacy. The oil palm fruit contains a cocktail of phenolics, and palm oil production results in high volumes of aqueous by-products enriched in phenolics and bioactives. Several lines of evidence from in vitro and in vivo animal studies confirmed that the aqueous extract enriched in phenolics and other bioactives collectively known as oil palm phenolics (OPP) is safe and has potent bioactivity. A phase one clinical trial was conducted to evaluate the safety and effects of OPP in healthy volunteers. In this single-blind trial, 25 healthy human volunteers were supplemented with 450 mg gallic acid equivalent (GAE)/day of OPP or control treatments for a 60-day period. Fasting blood and urine samples were collected at days 1, 30 and 60. Medical examination was performed during these trial interventions. All clinical biochemistry profiles observed throughout the control and OPP treatment period were in the normal range with no major adverse effect (AE) or serious adverse effect (SAE) observed. Additionally, OPP supplementation resulted in improvement of total cholesterol and LDL-C levels, compared to the control treatment. The outcomes support our previous observations that OPP is safe and may have a protective role in reducing cholesterol levels.Syed FairusSoon-Sen LeowIsa Naina MohamedYew-Ai TanKalyana SundramRavigadevi SambanthamurthiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-11 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Syed Fairus Soon-Sen Leow Isa Naina Mohamed Yew-Ai Tan Kalyana Sundram Ravigadevi Sambanthamurthi A phase I single-blind clinical trial to evaluate the safety of oil palm phenolics (OPP) supplementation in healthy volunteers
description	Abstract Plant phenolics are being increasingly consumed globally with limited scientific and clinical evidence pertaining to safety and efficacy. The oil palm fruit contains a cocktail of phenolics, and palm oil production results in high volumes of aqueous by-products enriched in phenolics and bioactives. Several lines of evidence from in vitro and in vivo animal studies confirmed that the aqueous extract enriched in phenolics and other bioactives collectively known as oil palm phenolics (OPP) is safe and has potent bioactivity. A phase one clinical trial was conducted to evaluate the safety and effects of OPP in healthy volunteers. In this single-blind trial, 25 healthy human volunteers were supplemented with 450 mg gallic acid equivalent (GAE)/day of OPP or control treatments for a 60-day period. Fasting blood and urine samples were collected at days 1, 30 and 60. Medical examination was performed during these trial interventions. All clinical biochemistry profiles observed throughout the control and OPP treatment period were in the normal range with no major adverse effect (AE) or serious adverse effect (SAE) observed. Additionally, OPP supplementation resulted in improvement of total cholesterol and LDL-C levels, compared to the control treatment. The outcomes support our previous observations that OPP is safe and may have a protective role in reducing cholesterol levels.
format	article
author	Syed Fairus Soon-Sen Leow Isa Naina Mohamed Yew-Ai Tan Kalyana Sundram Ravigadevi Sambanthamurthi
author_facet	Syed Fairus Soon-Sen Leow Isa Naina Mohamed Yew-Ai Tan Kalyana Sundram Ravigadevi Sambanthamurthi
author_sort	Syed Fairus
title	A phase I single-blind clinical trial to evaluate the safety of oil palm phenolics (OPP) supplementation in healthy volunteers
title_short	A phase I single-blind clinical trial to evaluate the safety of oil palm phenolics (OPP) supplementation in healthy volunteers
title_full	A phase I single-blind clinical trial to evaluate the safety of oil palm phenolics (OPP) supplementation in healthy volunteers
title_fullStr	A phase I single-blind clinical trial to evaluate the safety of oil palm phenolics (OPP) supplementation in healthy volunteers
title_full_unstemmed	A phase I single-blind clinical trial to evaluate the safety of oil palm phenolics (OPP) supplementation in healthy volunteers
title_sort	phase i single-blind clinical trial to evaluate the safety of oil palm phenolics (opp) supplementation in healthy volunteers
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/629fde5c12244eb9a11929d484d9d76e
work_keys_str_mv	AT syedfairus aphaseisingleblindclinicaltrialtoevaluatethesafetyofoilpalmphenolicsoppsupplementationinhealthyvolunteers AT soonsenleow aphaseisingleblindclinicaltrialtoevaluatethesafetyofoilpalmphenolicsoppsupplementationinhealthyvolunteers AT isanainamohamed aphaseisingleblindclinicaltrialtoevaluatethesafetyofoilpalmphenolicsoppsupplementationinhealthyvolunteers AT yewaitan aphaseisingleblindclinicaltrialtoevaluatethesafetyofoilpalmphenolicsoppsupplementationinhealthyvolunteers AT kalyanasundram aphaseisingleblindclinicaltrialtoevaluatethesafetyofoilpalmphenolicsoppsupplementationinhealthyvolunteers AT ravigadevisambanthamurthi aphaseisingleblindclinicaltrialtoevaluatethesafetyofoilpalmphenolicsoppsupplementationinhealthyvolunteers AT syedfairus phaseisingleblindclinicaltrialtoevaluatethesafetyofoilpalmphenolicsoppsupplementationinhealthyvolunteers AT soonsenleow phaseisingleblindclinicaltrialtoevaluatethesafetyofoilpalmphenolicsoppsupplementationinhealthyvolunteers AT isanainamohamed phaseisingleblindclinicaltrialtoevaluatethesafetyofoilpalmphenolicsoppsupplementationinhealthyvolunteers AT yewaitan phaseisingleblindclinicaltrialtoevaluatethesafetyofoilpalmphenolicsoppsupplementationinhealthyvolunteers AT kalyanasundram phaseisingleblindclinicaltrialtoevaluatethesafetyofoilpalmphenolicsoppsupplementationinhealthyvolunteers AT ravigadevisambanthamurthi phaseisingleblindclinicaltrialtoevaluatethesafetyofoilpalmphenolicsoppsupplementationinhealthyvolunteers
_version_	1718388390011863040

A phase I single-blind clinical trial to evaluate the safety of oil palm phenolics (OPP) supplementation in healthy volunteers

Ejemplares similares